// App-Quantinova.ai

S5002 2016 AHA : Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Researchers

Presenter

  • Huseyin Ince

Principal Investigators

  • Alexandre Abizaid

  • Soo Teik Lim

  • Javier Escaned

  • Hector Garcia-Garcia

  • Ron Waksman

  • Ralph Toelg

  • Pedro Lemos

  • Clemens von Birgelen

  • Evald Hoj Christiansen

  • William Wijns

  • Franz-Josef Neumann

  • Christoph Kaiser

  • Eric Eeckhout

Medical Centers

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • InCor, Insto do Coracao, Sao Paulo, Brazil

  • Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany

  • Medstar Washington Hosp Ctr, Washington, DC

  • OLV-Ziekenhuis Aalst, Aalst, Belgium

  • Aarhus University Hospital, Aarhus, Denmark

  • Medisch Spectrum Twente, Thoraxcentrum Twente, Enschede, Netherlands

  • Natl Univ Heart Ctr, Singapore, Singapore

  • Segeberger Kliniken, Bad Segeberg, Germany

  • University Hospital Basel, Basel, Switzerland

  • H C San Carlos, Madrid, Spain

  • ICU, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  • Stadtische Kliniken Neuss, Lukaskrankenhaus GmbH

Locations

  • Brazil

  • Netherlands

  • Singapore

  • Germany

  • Spain

  • Switzerland

  • United States

  • Denmark

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Nitroglycerin

  • Acetylcholine

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved